Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common
-
Shares outstanding
-
229M
-
Number of holders
-
111
-
Total 13F shares, excl. options
-
94.4M
-
Shares change
-
+864K
-
Total reported value, excl. options
-
$94.2M
-
Value change
-
+$447K
-
Put/Call ratio
-
0.01
-
Number of buys
-
39
-
Number of sells
-
-35
-
Price
-
$1.00
Significant Holders of Lineage Cell Therapeutics, Inc. - Common (LCTX) as of Q2 2024
123 filings reported holding LCTX - Lineage Cell Therapeutics, Inc. - Common as of Q2 2024.
Lineage Cell Therapeutics, Inc. - Common (LCTX) has 111 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 94.4M shares
of 229M outstanding shares and own 41.25% of the company stock.
Largest 10 shareholders include BROADWOOD CAPITAL INC (41.7M shares), BlackRock Inc. (9.56M shares), VANGUARD GROUP INC (8.47M shares), Defender Capital, LLC. (4.97M shares), Logos Global Management LP (4.7M shares), RAFFLES ASSOCIATES LP (4.36M shares), GEODE CAPITAL MANAGEMENT, LLC (3.6M shares), STATE STREET CORP (2.56M shares), MAI Capital Management (1.64M shares), and BANK OF AMERICA CORP /DE/ (1.36M shares).
This table shows the top 111 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.